Ahnaou A, Raeyemaekers L, Huysmans H, Drinkenburg W H I M
Dept. of Neuroscience Discovery, Janssen Research & Development, A Division of Janssen Pharmaceutica NV. Turnhoutseweg 30, B-2340 Beerse, Belgium.
Dept. of Neuroscience Discovery, Janssen Research & Development, A Division of Janssen Pharmaceutica NV. Turnhoutseweg 30, B-2340 Beerse, Belgium.
Behav Brain Res. 2016 Sep 15;311:287-297. doi: 10.1016/j.bbr.2016.05.035. Epub 2016 May 17.
The metabotropic glutamate receptor type 7 (mGluR7), a most abundant presynaptic G protein-coupled receptor in the brain provides an attractive mechanism to fast fine-tune abnormal excitatory neurotransmission and synaptic plasticity associated with emotional and cognitive impairments in neuropsychiatric and neurodegenerative disorders. Preclinical studies using AMN082, the mGluR7 allosteric agonist, produced conflicting results, so that results of further in-vivo studies are needed. Here, we investigated effects of subcutaneous administration at the lights onset of AMN082 on sleep-wake architecture and spectral contents in rats. In an attempt to solve the reported mixed results, we estimated the specific functional effects in mGluR7 (-/-) mice and their wild type (WT) littermates. In rats, AMN082 (2.5mg/kg) elicited a primary waking effect over the first 2h post-administration by consistent increases in the number of waking bouts and transitions from sleep states towards wakefulness. In mice, baseline recordings over 72h showed comparable spontaneous sleep-wake cycle in mGluR7 (-/-) mice and their WT littermates, suggesting that mGluR7 is not involved in the regulation of vigilance states. Remarkably, cortical arousal properties of AMN082 were confirmed in WT mice, and occurred concomitantly with a marked decrease in body temperature, likely dissociated from locomotor activity. Surprisingly, the wake arousal and hypothermia effects of AMN082 were also observed in mGluR7 (-/-) mice. AMN082 significantly attenuated the slow wave activity during sleep and had no effect on waking EEG power in the 4-50Hz range. The present findings in rats do not lend support to proposed somnogenic effects of AMN082, while comparable responses in WT and mGluR7 (-/-) mice provide further evidence of an off-target action of AMN082 that contributes to its waking properties.
代谢型谷氨酸受体7(mGluR7)是大脑中最丰富的突触前G蛋白偶联受体,为快速微调与神经精神疾病和神经退行性疾病中情绪和认知障碍相关的异常兴奋性神经传递及突触可塑性提供了一种有吸引力的机制。使用mGluR7变构激动剂AMN082的临床前研究产生了相互矛盾的结果,因此需要进一步进行体内研究。在此,我们研究了在光照开始时皮下注射AMN082对大鼠睡眠-觉醒结构和频谱成分的影响。为了解决所报道的混合结果,我们评估了mGluR7基因敲除(-/-)小鼠及其野生型(WT)同窝小鼠的特定功能效应。在大鼠中,AMN082(2.5mg/kg)在给药后的前2小时内通过持续增加觉醒次数以及从睡眠状态向觉醒状态的转变引发了主要的觉醒效应。在小鼠中,72小时的基线记录显示mGluR7(-/-)小鼠及其WT同窝小鼠的自发睡眠-觉醒周期具有可比性,这表明mGluR7不参与警觉状态的调节。值得注意的是,AMN082在WT小鼠中证实了皮质唤醒特性,并且与体温显著降低同时发生,这可能与运动活动无关。令人惊讶的是,在mGluR7(-/-)小鼠中也观察到了AMN082的唤醒觉醒和体温过低效应。AMN082显著减弱了睡眠期间的慢波活动,并且对4-50Hz范围内的觉醒脑电图功率没有影响。大鼠的当前研究结果不支持AMN082具有促睡眠作用的提议,而WT和mGluR7(-/-)小鼠中的类似反应提供了进一步证据,证明AMN082的脱靶作用有助于其唤醒特性。